Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;2003(4):CD003340.
doi: 10.1002/14651858.CD003340.

Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization

Mark B Loeb  1 , Cheryl Main, Angela Eady, Cindy Walker-Dilks
Affiliations

Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization

Mark B Loeb et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: Eradication strategies for methicillin-resistant Staphylococcus aureus (MRSA) are variable. We sought to summarize the evidence for use of antimicrobial agents to eradicate MRSA.

Objectives: To describe the effects of topical and systemic antimicrobial agents on nasal and extra-nasal MRSA carriage, adverse events, and incidence of subsequent MRSA infections.

Search strategy: We searched the Cochrane Infectious Diseases Group's trials register (August 2003), the Cochrane Central Register of Controlled Trials (Issue 3, 2003), MEDLINE (1966 to 2003), EMBASE (1988 to 2003), handsearched relevant literature, and contacted MRSA experts and the manufacturer of mupirocin.

Selection criteria: Randomized controlled trials of patients colonized with MRSA comparing topical or systemic antimicrobials to placebo or no treatment, and trials comparing various combinations of topical or systemic agents to no treatment, placebo, or to topical or systemic agents.

Data collection and analysis: Two reviewers independently applied inclusion criteria to potentially relevant trials, assessed trial methodological quality, and extracted data. Primary outcomes included eradication of MRSA, infection due to MRSA, and adverse events.

Main results: Six trials (384 participants) met the inclusion criteria. No difference in MRSA eradication was detected in four studies: one that compared mupirocin to placebo, two that compared one systemic agent to no treatment (fusidic acid in one and rifampin or minocycline in the other) and one that compared mupirocin to topical fusidic acid and oral trimethoprim-sulfamethoxazole, examining nasal MRSA eradication as an outcome. One study compared minocycline to rifampin, with rifampicin being more effective in relation to eradication of MRSA from all sites at day 30 (relative risk 0.16; 95% confidence intervals 0.02 to 1.00), but the difference at 90 days was not statistically significant (n = 18). Two studies (one testing novobiocin and rifampin, the other ciprofloxacin and rifampin, versus trimethoprim-sulfamethoxazole and rifampin) did not demonstrate a difference in eradication of MRSA at all sites (n = 94). Adverse events with systemic agents occurred in up to 20% of participants, however reporting was sporadic and denominators small. All trials reported development of resistance to antimicrobial agents used.

Reviewer's conclusions: There is insufficient evidence to support use of topical or systemic antimicrobial therapy for eradicating nasal or extra-nasal MRSA. There is no demonstrated superiority of either topical or systemic therapy, or of combinations of these agents. Potentially serious adverse events and development of antimicrobial resistance can result from therapy.

PubMed Disclaimer

Conflict of interest statement

We certify that we have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter of the review (e.g. employment, consultancy, stock ownership, honoraria, expert testimony).

Figures

1.1
1.1. Analysis
Comparison 1 One topical agent versus placebo, Outcome 1 Eradication of MRSA from all sites.
1.2
1.2. Analysis
Comparison 1 One topical agent versus placebo, Outcome 2 Nasal MRSA eradication.
1.3
1.3. Analysis
Comparison 1 One topical agent versus placebo, Outcome 3 MRSA infection.
2.1
2.1. Analysis
Comparison 2 One systemic agent versus no treatment, Outcome 1 Eradication of MRSA from all sites (day 30).
2.2
2.2. Analysis
Comparison 2 One systemic agent versus no treatment, Outcome 2 Eradication of MRSA from all sites (day 90).
3.1
3.1. Analysis
Comparison 3 Two systemic agents versus no treatment, Outcome 1 Eradication of MRSA from all sites (day 30).
3.2
3.2. Analysis
Comparison 3 Two systemic agents versus no treatment, Outcome 2 Eradication of MRSA from all sites (day 90).
4.1
4.1. Analysis
Comparison 4 One topical versus one topical and one systemic agent, Outcome 1 Eradication of nasal MRSA.
5.1
5.1. Analysis
Comparison 5 One systemic agent versus one systemic agent, Outcome 1 Eradication of MRSA from all sites (day 30).
5.2
5.2. Analysis
Comparison 5 One systemic agent versus one systemic agent, Outcome 2 Eradication of MRSA from all sites (day 90).
6.1
6.1. Analysis
Comparison 6 Two systemic agents versus one systemic agent, Outcome 1 Eradication of MRSA from all sites (day 30).
6.2
6.2. Analysis
Comparison 6 Two systemic agents versus one systemic agent, Outcome 2 Eradication of MRSA from all sites (day 90).
6.3
6.3. Analysis
Comparison 6 Two systemic agents versus one systemic agent, Outcome 3 Eradication of MRSA from all sites (day 14).
See this image and copyright information in PMC

References

References to studies included in this review

Chang 2000 {published data only}
    1. Chang SC, Hsieh SM, Chen ML, Sheng WH, Chen YC. Oral fusidic acid fails to eradicate methicillin‐resistant Staphylococcus aureus colonization and results in emergence of fusidic acid‐resistant strains. Diagnostic Microbiology and Infectious Disease 2000;36:131‐6. - PubMed
Harbarth 1999 {published data only}
    1. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo‐controlled, double‐blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin‐resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 1999;43(6):1412‐6. - PMC - PubMed
Muder 1994 {published data only}
    1. Muder RR, Bolden M, Brennen C, Vickers RM, Mitchum K, Yee YC. A controlled trial of rifampin, minocycline, and rifampin plus minocycline for eradication of methicillin‐resistant Staphylococcus aureus in long‐term care patients. Journal of Antimicrobial Chemotherapy 1994;34:188‐90. - PubMed
Parras 1995 {published data only}
    1. Parras F, Guerrero MC, Bouza E, Blazquez MJ, Moreno S, Cruz Menarguez M, et al. Comparative study of mupirocin and oral co‐trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin‐resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 1995;39(1):175‐9. - PMC - PubMed
Peterson 1990 {published data only}
    1. Peterson LR, Quick JN, Jensen B, Homann S, Johnson S, Tenquist J, et al. Emergence of ciprofloxacin resistance in nosocomial methicillin‐resistance Staphylococcus aureus isolates. Archives of Internal Medicine 1990;150:2151‐5. - PubMed
Walsh 1993 {published data only}
    1. Walsh TJ, Standiform HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized double‐blinded trial of rifampin with either novobiocin or trimethoprim‐sulfamethoxazole against methicillin‐resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrobial Agents and Chemotherapy 1993;37(6):1134‐42. - PMC - PubMed

References to studies excluded from this review

Asenio 1996 {published data only}
    1. Asensio A, Guerrero A, Quereda C, Lizan M, Matinez‐Ferrer. Colonization and infection with methicillin‐resistant staphylococcus aureus: Associated factors and eradication. Infection Control and Hospital Epidemiology 1996;17:20‐9. - PubMed
Brun‐Boisson 1994 {published data only}
    1. Brun‐Buisson C, Rauss A, Legrand P, Mentec H, Ossart M, Eb F, et al. Treatment of nasal colonization of MRSA using mupirocin and prevention of infection: a controlled multi‐center study [Traitement du portage nasal de Staphylococcus aureus par la mupirocine nasale et prévention des infections acquises en réanimation. Etude multicentrique contrôlée]. Medecine et Maladies Infectieuses 1994;24:1229‐39.
Caelli 2000 {published data only}
    1. Caelli M, Porteous J, Carson CF, Heller R, Riley TV. Tea tree oil as an alternative topical decolonization agent for methicillin‐resistant Staphylococcus aureus. Journal of Hospital Infection 2000;46:236‐7. - PubMed
Chandler 1990 {published data only}
    1. Chandler MH, Toler SM, Rapp RP, Muder RR, Korvick JA. Multiple‐dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. Antimicrobial Agents and Chemotherapy 1990;34:442‐7. - PMC - PubMed
Dacre 1983 {published data only}
    1. Dacre JE, Emmerson AM, Jenner EA. Nasal carriage of gentamicin and methicillin resistant Staphylococcus aureus treated with topical pseudomonic acid. Lancet 1983;2(8357):1036. - PubMed
Darouiche 1991 {published data only}
    1. Darouche R, Wright C, Hamill R, Koza M, Lewis D, Markowski J. Eradication of colonization by methicillin‐resistant Staphylococcus aureus by using oral minocycline‐rifampin and topical mupirocin. Antimicrobial Agents and Chemotherapy 1991;35:1612‐5. - PMC - PubMed
Kato 1994 {published data only}
    1. Kato K, Okuda K, Uedono M, Ishikura H, Takeyama N, Tanaka T. Lysozyme chloride and ß‐lactam antibiotics, efficacy of concomitant administration against methicillin‐resistant Staphylococcus aureus (MRSA), a basic and clinical study. Chemotherapy 1994;42:42‐6.
Kauffman 1993 {published data only}
    1. Kauffman CA, Terpenning MS, He X, Zarins LT, Ramsey MA, Jorgensen KA, et al. Attempts to eradicate methicillin‐resistant Staphylococcus aureus fraom a long‐term‐care facility with the use of mupirocin ointment. American Journal of Medicine 1993;94:371‐8. - PubMed
Kidson 1979 {published data only}
    1. Kidson A, Lilly HA, Lowbury EJL. Flocloxacillin treatment of methicillin‐'resistant' and sensitive staphylococcal infection. Journal of Antimicrobial and Chemotherapy 1979;5:359‐64. - PubMed
Kimata 1999 {published data only}
    1. Kimata H. Effect of nadifloxacin on atopic dermatitis with methicillin‐resistant Staphylococcus aureus in young children. European Journal of Pediatrics 1999;158:949‐54. - PubMed
Kono 1994 {published data only}
    1. Kono K, Takeda S, Tatara I. Clinical trial of roxithromycin against respiratory tract infection and colonization of methicillin‐resistant Staphylococcus aureus. Chemotherapy 1994;42:1259‐68.
Lowbury 1977 {published data only}
    1. Lowbury EJL, Lilly HA, Kidson A. "Methicillin‐resistant" Staphylococcus aureus: reassessment by controlled trial in burns unit. British Medical Journal 1977;1:1054‐6. - PMC - PubMed
Mulligan 1987 {published data only}
    1. Mulligan ME, Ruane PJ, Johnston L, Wong P, Wheelock JP, MacDonald K, et al. Ciprofloxacin for eradication of methicillin‐resistant Staphylococcus aureus colonization. American Journal of Medicine 1987;82(4A):215‐9. - PubMed
Okano 2000 {published data only}
    1. Okano M, Noguchi S, Tabata K, Matsumoto Y. Topical gentian violet for cutaneous infection and nasal carriage with MRSA. International Journal of Dermatology 2000;39:942‐4. - PubMed
Redhead 1991 {published data only}
    1. Redhead RJ, Lamb YL, Rowsell RB. The efficacy of calcium mupirocin in the eradication of nasal Staphylococus aureus carriage. British Journal of Clinical Practice 1991;45(4):252‐4. - PubMed
Rode 1989 {published data only}
    1. Rode H, Hanslo D, Wet PM, Millar AJW, Cywes S. Efficacy of mupirocin in methicillin‐resistant Staphylococcus aureus brun wound infection. Antimicrobial Agents and Chemotherapy 1989;33:1358‐61. - PMC - PubMed
Saji 1995 {published data only}
    1. Saji M, Taguchi S, Uchiyama K, Osono E, Hayama N, Ohkuni H. Efficacy of gentian violet in the eradication of methicillin‐resistant Staphylococcus aureus fron skin lesions. Journal of Hospital Infection 1995;31:225‐8. - PubMed
Shirai 1995 {published data only}
    1. Shirai M, Ide K, Sato M, Murakami M, Tanaka Y, Sato A, et al. Effect of inhaled vancomycin hydrochloride on elimination of methicillin‐resistant Staphylococcus aureus. Nihon Kyobu Shikkan Gakkai Zasshi 1995;33:1233‐9. - PubMed
Sloot 1999 {published data only}
    1. Sloot N, Siebert J, Höffler U. Eradication of MRSA from carriers by means of whole‐body washing with an antiseptic in combination with mupirocin nasal ointment. Zentralblatt fur Hygiene und Umweltmedizin (International Journal of Hygiene and Environmental Medicine) 1999;202:513‐23. - PubMed
Smith 1989 {published data only}
    1. Smith SM, Eng RH, Tecson‐Tumang F. Ciprofloxacin therapy for methicillin‐resistant staphylococcus aureus infections or colonizations. Antimicrobial Agents and Chemotherapy 1989;33:181‐4. - PMC - PubMed
Soga 1999 {published data only}
    1. Soga Y. Efficacy of mupirocin in eradicating methicillin‐resistant Staphylococcus aureus from nasal discharge in carrying cardiovascular surgical patients. Kyobu Geka 1999;52:735‐8. - PubMed
Toba 1997 {published data only}
    1. Toba K, Sudoh N, Nagano K, Eto M, Mizuno Y, Nakagawa H, et al. Randomized prospective trial of gentian violet with dibutyryl cAMP and poviodine‐iodine with sugar as treatment for pressure sores infected with methicillin‐resistant Staphylococcus aureus in elderly patients. Japanese Journal of Geriatrics 1977;34:577‐82. - PubMed
Watanakunakorn 1995 {published data only}
    1. Watanakunakorn C, Axelson C, Bota B, Stahl C. Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents. American Journal of Infection Control 1995;23:306‐9. - PubMed
Yamada 1997 {published data only}
    1. Yamada M, Takahashi R, Chiba Y, Ito T, Nakae S. Methicillin‐resistant Staphylococcus aureus in a neonatal intensive care unit II. The effect of nasopharyngeal disinfection with poviodine‐iodine solution. Nippon Shineiji Gakkai Zasshi 1997;33(3):341‐7.
Yoshida 1997 {published data only}
    1. Yoshida T, Ohura T, Sugihara T. Clinical efficacy of silver sulfadiazine (AgSD:GEBEN® cream) for ulcerative skin lesions infected with MRSA. Japanese Journal of Antibiotics 1997;50:39‐44. - PubMed

References to studies awaiting assessment

Dupeyron 2002 {published data only}
    1. Dupeyron C, Campillo B, Bordes M, Faubert E, Richardet JP, Mangeney N. A clinical trial of mupirocin in the eradication of methicillin‐resistant Staphylococcus aureus nasal carriage in a digestive disease unit. The Journal of hospital infection 2002;52(4):281‐7. - PubMed
Ellis 2003 {published data only}
    1. Ellis SL, Finn P, Noone M, Leaper DJ. Eradication of methicillin‐resistant Staphylococcus aureus from pressure sores using warming therapy. Surgical infections 2003;4(1):53‐5. - PubMed
Takahashi 2003 {published data only}
    1. Takahashi S, Minami K, Ogawa M, Miyamoto H, Ikemura K, Shigematsu A, et al. The preventive effects of mupirocin against nasotracheal intubation‐related bacterial carriage. Anesthesia and analgesia 2003;97(1):222‐5. - PubMed
Yamada 2003 {published data only}
    1. Yamada H, Ohashi K, Atsumi T, Okabe H, Shimizu T, Nishio S, et al. Effects of tea catechin inhalation on methicillin‐resistant Staphylococcus aureus in elderly patients in a hospital ward. The Journal of hospital infection 2003;53(3):229‐31. - PubMed

Additional references

Ayliffe 1974
    1. Ayliffe GAJ. Methicillin‐resistant Staphylococcus aureus. Lancet 1974;1:573. - PubMed
Ayliffe 1996
    1. Ayliffe AJ. Recommendations for the control of methicillin‐resistant Staphylococcus aureus (MRSA) (www.who.int/emc‐documents/antimicrobial_resistance/docs/1whoemclts961.pdf). Geneva: World Health Organization, 1996 (accessed 15 June 2001).
Casewell 1986a
    1. Casewell MW. Epidemiology and the control of 'modern' methicillin‐resistant Staphylococcus aureus. Journal of Hospital Infection 1986;7 Suppl A:1‐11. - PubMed
Casewell 1986b
    1. Casewell MW, Hill RL. Elimination of nasal carriage of Staphylococcal aureus with mupirocin ('pseudomonic acid') ‐ a controlled trial. Journal of Antimicrobial Chemotherapy 1986;17(3):365‐72. - PubMed
Clarke 2003
    1. Clarke M, Oxman A, editors. Optimal search strategy. Cochrane Reviewer's Handbook 4.2 [updated March 2003]; Appendix 5c. In: The Cochrane Library [database on disc and CDROM]. The Cochrane Collaboration. Chichester: Wiley; 2003, issue 3.
Fernandez 1995
    1. Fernandez C, Gaspar C, Torrellas A, Vindel A, Saez ‐ Nietoa JA, Cruzet F, et al. A double‐blind, randomized, placebo‐controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. Journal of Antimicrobial Chemotherapy 1995;35(3):339‐408. - PubMed
Livermore 2000
    1. Livermore DM. Antibiotic resistance in staphylococci. International Journal of Antimicrobial Agents 2000;16 Suppl 1:3‐10. - PubMed
Mulligan 1993
    1. Mulligan ME, Murray‐Leisure KA, Ribner BS, Stadiform HC, John JF, Korvick JA, et al. Methicillin‐resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. American Journal of Medicine 1993;94:312‐28. - PubMed
Paradisi 2001
    1. Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Medical Clinics of North America 2001;85(1):1‐17. - PubMed
Pujol 1996
    1. Pujol M, Pena C, Pallares R, Ariza J, Ayat SJ, Dominguez MA, et al. Nosocomial Staphylococcus bacteremia among nasal carriers of methicillin‐resistant and methicillin‐susceptible strains. American Journal of Medicine 1996;100(5):509‐16. - PubMed
Scully 1992
    1. Scully BE, Brianes F, Gu JW, Neu HC. Mupirocin treatment of nasal staphylococcal colonization. Archives of Internal Medicine 1992;152(2):353‐6. - PubMed
Selvey 2000
    1. Selvey LA, Whitby M, Johnson B. Nosocomial methicillin‐resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial methicillin sensitive Staphylococcus aureus bacteremia?. Infection Control and Hospital Epidemiology 2000;10:645‐8. - PubMed
Sieradzki 1999
    1. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin‐resistant Staphylococcus aureus infection. New England Journal of Medicine 1999;340(7):517‐23. - PubMed
Sievert 2002
    1. Sievert DM, Boulton ML, Stoltman G, Johnson D, Stobierski MG, Downes FP, et al. Staphylococcus aureus resistant to vancomycin ‐ United States, 2002. Morbidity and Mortality Weekly Report 2002;51(26):565‐7. - PubMed
Smith 1999
    1. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson‐Dunn B, et al. Emergence of vancomycin resistant in Staphylococcus aureus. Glycopeptide Intermedicate Working Group. New England Journal of Medicine 1999;340(7):493‐501. - PubMed
Waldvogel 1995
    1. Waldvogel F. Staphylococcus aureus. In: Mandell GL, Bennett JE, Dolin R editor(s). Principles and practice of infectious diseases. 4th Edition. New York: Churchill Livingstone, 1995:1754‐8.

Publication types

MeSH terms

Substances

LinkOut - more resources